Werewolf Therapeutics (HOWL) vs SCYNEXIS (SCYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SCYNEXIS (SCYX) has outperformed Werewolf Therapeutics (HOWL) over the past year, losing 32.1% versus a loss of 51.6%. Over five years, SCYX leads with a -90.5% price change compared with -94.7% for HOWL. Werewolf Therapeutics is the larger company by market cap ($47.6 million vs $40.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HOWL | SCYX |
|---|---|---|
| Share price | $0.9793 | $4.09 |
| Market cap | $47.60M | $40.69M |
| 1-day change | +7.61% | -3.08% |
| YTD return | +43.53% | -16.53% |
| 1-year return | -51.60% | -32.11% |
| 5-year return | -94.67% | -90.53% |
| EPS (TTM) | $-0.73 | $-0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.85 | $9.12 |
| 52-week low | $0.27 | $3.53 |
| Distance from 52-week high | -47.06% | -55.15% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +614.80% | +788.26% |
| Average volume | 6.80M | 279.10K |
| Shares outstanding | 48.60M | 9.95M |
| Employees | 39 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SCYX has outperformed HOWL by 19.5 percentage points over the past year.
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
HOWL vs SCYX FAQ
Which is bigger, Werewolf Therapeutics or SCYNEXIS?
Werewolf Therapeutics (HOWL) is larger, with a market capitalization of $47.60M compared with $40.69M for SCYNEXIS (SCYX).
Which stock has performed better over the past year, HOWL or SCYX?
SCYX returned -32.11% over the past 12 months, compared with -51.60% for HOWL (price return, excluding dividends). Past performance does not predict future results.
Are Werewolf Therapeutics and SCYNEXIS in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.